Sangamo Therapeutics
Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.
Biotechnology company developing gene therapies and genome editing.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
15-Year watch begins for experimental transplant therapy
Disease control OngoingThis study follows 11 kidney transplant patients who received an experimental cell therapy called TX200-TR101 in an earlier trial. Researchers will monitor them for up to 15 years to check for long-term side effects and how well their transplanted kidney is doing. The goal is to …
Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene therapy patients monitored for years to ensure lasting safety
Disease control OngoingThis study follows 8 people who received a one-time gene therapy (BIVV003 for sickle cell disease or ST-400 for beta-thalassemia) to see if it remains safe and effective over many years. Researchers will track serious side effects, survival, and blood markers like hemoglobin leve…
Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC